Mesoblast's cell therapy shows durable treatment effect in mid-stage study; shares ahead 4%

|About: Mesoblast (MESO)|By:, SA News Editor

Ultra-thinly traded micro cap Mesoblast (MESO +3.7%) perks up on average volume in response to its announcement of positive long-term results from a 100-subject Phase 2 study assessing its proprietary allogeneic Mesenchymal Precursor Cells (MPCs) in patients with chronic low back pain due to disc degeneration.

The data showed a single intra-discal injection of 6M MPCs produced meaningful improvements in pain and function that persisted for at least 36 months.

The 36-month data support the ongoing 360-patient Phase 3 study of MPC-06-ID by reinforcing the rationale of MPC dose selection.

The company is in negotiations with Mallinckrodt for commercialization rights.